Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

N/ACompletedNCT00419484

Dokkyo Medical University1,000 enrolled

Overview

We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.

Primary composite endpoints: Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine) Secondary endpoints: urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Type 2 Diabetes Hypertension Dyslipidemia Diabetic Nephropathy

Interventions

pioglitazoneDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * type 2 diabetes HbA1c: more than 7% and less than 9% Exclusion Criteria: * insulin treatment

Locations (1)

Dokkyo Medical University, Koshigaya Hospital

Koshigaya, Saitama, Japan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.